Should We Sequence the DNA of Every Cancer Patient?
By Antonio Regalado,
MIT Technology Review
| 06. 14. 2016
A startup called Strata Oncology says it plans to give away advanced genetic tests to 100,000 patients struggling with cancer. But there's a profit motive: it hopes to identify patients with specific rare DNA errors and steer them to drug companies.
Strata, which was founded last year and has raised $12 million from investors, says it is set up to run 50,000 next-generation sequencing tests a year. Such tests probe the DNA of tumor tissue, searching for mutations in hundreds of genes at once, hoping to surface clues about what drug a patient should be taking.
Similar tests are already offered commercially to doctors by several companies, including Foundation Medicine of Cambridge, Massachusetts, and can cost $5,000 each.
Continue reading on MIT Technology Review
Image via Wikipedia
Related Articles
By Fyodor Urnov, The CRIPSR Journal | 10.18.2024
The field of clinical gene editing has a bona fide crisis on its hands—a crisis that has to, and can be, promptly resolved.
An outside observer of our field might be surprised by this and say—what crisis? The first...
By Walt Bogdanich and Carson Kessler, The New York Times | 10.23.2024
By 2021, nearly 2,000 volunteers had answered the call to test an experimental Alzheimer’s drug known as BAN2401. For the drugmaker Eisai, the trial was a shot at a windfall — potentially billions of dollars — for defanging a disease...
By Ashleigh Wyss [cites CGS' Katie Hasson], Listnr | 10.09.2024
Discovering your genetic history can be as simple as spitting into a test tube, but what happens when your data ends up in the wrong hands?
With at-home DNA test kits becoming increasingly popular throughout the 2010s, curious consumers have...
By Kevin Davies , Genetic Engineering and Biotechnology News | 10.22.2024
